Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Tepmetko
|
| gptkbp:CASNumber |
1110733-69-1
|
| gptkbp:chemicalFormula |
C29H28N6O2
|
| gptkbp:developedBy |
gptkb:Merck_KGaA
|
| https://www.w3.org/2000/01/rdf-schema#label |
tepotinib
|
| gptkbp:indication |
MET exon 14 skipping mutation-positive NSCLC
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits MET phosphorylation
|
| gptkbp:molecularWeight |
492.6 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea edema fatigue |
| gptkbp:target |
gptkb:MET_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:c-Met
|
| gptkbp:bfsLayer |
6
|